Company intelligence / Profile preview

CellTherX

Houston or Dallas area, Texas, United States

Ownership: Private
Development stage: Other

Overview

CellTherX has developed proprietary Microsurfacing technology that enhances the efficacy of reconstructive tissue grafts by increasing their surface area, promoting better cellular integration, faster healing, and improved outcomes. Their IP is currently licensed in the dental market as Cytoplast Microderm. A recent clinical study led by Dr. Michael McGuire confirmed benefits over traditional allografts; publication is expected in late 2024.

Therapeutic areas: DermatologyOther
Modalities: Regenerative tissue graftsAcellular dermal matrixDecellularized amnion/chorion tissue
Industry: Biotech

Drug pipeline

1 asset

CTX-ADM

Unknown

Partnerships

Osteogenics Biomedical (licensee/distribution partner for dental market)

Beyond the preview

Go deeper on CellTherX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellTherX.

Explore the full profile